Jessica A. Pollard | Medical Services
Programs & Services
Jessica A. Pollard | Education
Medical School
Columbia University College of Physicians and Surgeons
2000, New York, NY
Residency
Seattle Children's Hospital/University of Washington
2003, Seattle, WA
Fellowship
Fred Hutchinson Cancer Research Center
Seattle Children’s Hospital/University of Washington
2006, Seattle, WA
Jessica A. Pollard | Professional History
Dr. Jessica Pollard joins the Hematologic Malignancies service as faculty member and clinical researcher. Dr. Pollard came to Dana-Farber after working as an attending at Seattle Children’s Hospital/Fred Hutchinson Cancer Research Center from 2006-2014. For the last 4 years she has been an attending at Maine Children’s Cancer Program at Maine Medical Center where she was an Attending Physician in the Division of Pediatric American Board of Pediatrics, Pediatric Hematology/Oncology Hematology/Oncology, and Associate Professor of Pediatrics at Tufts University School of Medicine.
Dr. Pollard received her B.S. degree, with Honors, in biology from Cornell University in 1995 and went on to earn her M.D. from Columbia University in 2000. She completed her residency in pediatrics at the University of Washington and Seattle Children’s Hospital before joining a joint pediatric hematology/oncology fellowship program with the Fred Hutchinson Cancer Research Center in 2003. Following the completion of her fellowship training, Dr. Pollard was faculty at the University of Washington and Seattle Children’s Hospital until 2014. She relocated to Maine in 2014 where she worked as an attending at Maine Children’s Cancer Program/Maine Medical Center until her relocation to Boston in 2018.
Dr. Pollard’s expertise lies in the management of children with myeloid malignancies. Her research focus is in development of clinical trials that improve outcomes in acute myeloid leukemia (AML) and related myeloid disorders by utilizing knowledge of disease biology to optimize treatment approaches. Moreover, she has an interest in germline conditions that predispose to myeloid malignancies and how such conditions impact treatment considerations.